Together, the two companies will develop biotech substrates for diagnostics applications.
The expertise of AMI will further strengthen Schott’s ability to offer a single-source contract manufacturing solution.
Through this acquisition, Schott Minifab significantly expands its biosensor printing capabilities.
Demand is said to be growing for the manufacturing of point-of-care microarray consumables, especially in applications such as infectious disease detection.
“We pride ourselves on being an end-to-end partner for the global diagnostics industry. Our expansive offering allows us to provide an integrated single-source collection of value-intensive services and products.
“With the added bioscience knowledge of AMI, we become an even stronger partner, enhancing our capability in surface modification, functionalization and deposition for both glass and polymer products,” said Greg Wolters, Head of Schott Minifab.
“We are joining SCHOTT at a time when the market continues to steer toward point-of-care diagnostics,” added Alastair Malcolm, CEO of AMI.
“Our joint knowledge and technical capability allow us to offer a more holistic approach while shortening the time to market for customers.”
AMI will soon be moving to a larger facility in the Phoenix, Arizona area.
Its new location will increase Schott’s manufacturing footprint in the United States to serve its global customer base.